GIP/GLP1 agonist compositions
A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
1. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof, wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.
2. A method of treating obesity as claimed by claim 1 wherein the dose is administered using an automatic injection apparatus.
3. A method of treating obesity as claimed by claim 2 wherein the dose is administered once weekly.
4. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;
NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and
dibasic sodium phosphate.
5. A method as claimed by claim 4 , wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL.
6. A method as claimed by claim 5 wherein the dibasic sodium phosphate concentration is from about 1 mg/mL to about 3 mg/mL.
7. A method as claimed by claim 4 wherein the dibasic sodium phosphate concentration is from about 0.67 mg/mL to about 2.68 mg/mL.
8. A method as claimed by claim 7 wherein the dibasic sodium phosphate concentration is about 1.34 mg/mL.
9. A method as claimed by claim 8 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL.
10. A method as claimed by claim 9 wherein the NaCl concentration is from about 7.0 mg/mL to about 9.0 mg/mL.
11. A method as claimed by claim 10 wherein the NaCl concentration is about 8.2 mg/mL.
12. A method as claimed by claim 1 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL.
13. A method as claimed by claim 12 wherein the NaCl concentration is from about 7.0 mg/mL to about 9.0 mg/mL.
14. A method as claimed by claim 13 wherein the NaCl concentration is about 8.2 mg/mL.
15. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising:
(a) tirzepatide, or pharmaceutically acceptable salt thereof, wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL;
(b) dibasic sodium phosphate, wherein the dibasic sodium phosphate concentration is about 1.34 mg/mL; and
(c) NaCl, wherein the NaCl concentration is about 8.2 mg/mL; and
wherein the dose is administered using an automatic injection apparatus.